Skip to main content
Premium Trial:

Request an Annual Quote

John Yingling, Richard Cramer, Dieter Schmidt-Base, James Rubin, Bryan Koontz, Mary Woodward, Mark Gessler, Charles Dimmler, Susie Stephens

Premium
Tripos said in an 8-K filing this week that John Yingling, CFO; Richard Cramer, CSO; and Dieter Schmidt-Base, senior vice president of worldwide sales; resigned from their positions with Tripos to accept positions with Vector Capital, which completed its acquisition of the Tripos Discovery Informatics business this week (see briefs). 
 
In addition, Tripos said that it has terminated the employment of James Rubin, senior vice president; Bryan Koontz, senior vice president of discovery informatics; and Mary Woodward, senior vice president of strategic development. 
 

 
Mark Gessler has stepped down as CEO of Gene Logic. The company’s board of directors elected Charles Dimmler to replace Gessler as president and CEO. Dimmler has worked for more than 20 years in life sciences financing and has served as a director of Gene Logic since 1996.
 
Gessler will remain on Gene Logic’s board of directors.
 

 
Susie Stephens, formerly senior product manager for Oracle's life sciences group, has left Oracle to join Eli Lilly as a principal research scientist.

Filed under

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.